I was drawn to pediatric neurology because of the variety of practice areas and the tremendous opportunities for developing new interventions, treatments and clinical practices for this special population.
Cameron A. Wade, MD, MPH

About

Biography

I practice general pediatrics and child neurology. I was drawn to pediatric neurology because of the variety of practice areas and the tremendous opportunities for developing new interventions, treatments and clinical practices for this special population.

My work with children was also inspired by clinician epidemiologists who incorporate population health into clinical practice.

As a medical student in Kentucky, I received the American Academy of Neurology Medical Student Award for Excellence and was elected to the Alpha Omega Alpha Honor Society.

In my free time, I enjoy rock climbing and video games.

MD: University of Kentucky, Lexington, KY, 2021

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

2.64eP QTc prolongation in an individual with Duchenne muscular dystrophy treated with givinostat and lessons for clinicians. Tian, C; Zygmunt, A; Reebals, L; Wade, C; Horn, P; Mcanally, M; Mantell, B; Villa, C. Neuromuscular Disorders. 2026; 67:106823.

2.36eP Assessing side effects of thrombocytopenia and hypertriglyceridemia for individuals with Duchenne muscular dystrophy treated with givinostat. Horn, P; Reebals, L; Zygmunt, A; Bramer, A; Mcanally, M; Wade, C; Tian, C. Neuromuscular Disorders. 2026; 67:106796.

2.17eP Fatal fat embolism syndrome without recognized fracture in patients with Duchenne muscular dystrophy: two case reports. Wade, C; Villa, C; Goldstein, LB; Tian, C; Zygmunt, A; Rice, K; Bagwell, L; Mcgovern, E; Toupin, DN. Neuromuscular Disorders. 2026; 67:106741.

2.13eP Tolerability of givinostat in combination with exon-skipping therapy in individuals with Duchenne muscular dystrophy. Wade, C; Bramer, A; Horn, P; Zygmunt, A; Reebals, L; Mcanally, M; Tian, C. Neuromuscular Disorders. 2026; 67:106737.

Fatal Fat Embolism Syndrome Without Recognized Fracture in Patients With Duchenne Muscular Dystrophy: Two Case Reports. Wade, CA; Villa, C; Goldstein, LB; Tian, C; Zygmunt, A; Rice, K; Bagwell, L; Mcgovern, E; Toupin, DN. Pediatric Neurology. 2026; 181:51-55.

A case report of a 19-year-old female with headaches, hearing loss, and pachymeningitis. Wade, CA; Kessler, H; Moehlman, M; Vater, M; Wilson, E. Neuroimmunology Reports. 2026; 9:100288.

186PPerformance of upper limb in steroid-treated Duchenne muscular dystrophy: genotype-phenotype correlations. Wade, C; Zygmunt, A; Horn, P; Bonarrigo, K; Reebals, L; Rybalsky, I; Tian, C. Neuromuscular Disorders. 2025; 53:105539.

Methenamine Prophylaxis for Recurrent Urinary Tract Infections in a Tertiary Referral Center. Wade, C; Lacy, ME; Harris, L; Goldwag, J; Erickson, DR. Urology Practice. 2021; 8(6):699-704.